Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1

Status

Completed 4Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic 1Neoplasms 1

Interventions

Prednisone 103enzalutamide 76Docetaxel 72Abiraterone Acetate 68Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 39apalutamide 29Prednisolone 27bicalutamide 26Zoledronic Acid 24radium Ra 223 dichloride 22pembrolizumab 22darolutamide 22Goserelin 22Triptorelin Pamoate 17cabazitaxel 16Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × fludrocortisone acetate × Clear all
NCT06136650 2026-06-03

MK-5684-004

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,314 enrolled
Genitourinary

Prostatic Neoplasms

NCT06104449 2026-04-27

MK-5684-005

Merck Sharp & Dohme LLC

Phase 1 Completed
7 enrolled
Genitourinary

Prostatic Neoplasms

NCT06136598 2026-03-19

MK-5684-001

Merck Sharp & Dohme LLC

Phase 1 Completed
14 enrolled
Genitourinary

Prostatic Neoplasms

NCT06566989 2024-10-23

MK-5684-008

Merck Sharp & Dohme LLC

Phase 1 Completed
8 enrolled
Genitourinary

Prostatic Neoplasms

NCT06554639 2024-10-15

MK-5684-011

Merck Sharp & Dohme LLC

Phase 1 Completed
12 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡